– BELGIUM, Zwijnaarde – Aphea.Bio, a Belgium-based agtech startup, today announced that it secured a € 14 million Series B round led by Astanor Ventures and joined by current shareholders V-Bio Ventures, Agri Investment Fund, PMV, Vives Fund, VIB, Qbic II and Gemma Frisius Fund.
This funding further strengthens Aphea.Bio’s plans to advance its biostimulant and bio-fungicide research and development programs towards submission of the regulatory dossier and to support the launch of the company’s first products. This new round of funding will also support expanded research and development in the areas of bioinsecticides and bioherbicides. With its broad pipeline, Aphea.Bio sets course to become the ‘one-stop-shop’ for biological product development.
“Astanor Ventures is the perfect lead investor in Aphea.Bio’s Series B funding,” said CEO, Isabel Vercauteren. “We both share the same ambition of making an impact on modern agriculture and to move towards a more healthy and sustainable food system”.
Hendrik Van Asbroeck, Partner at Astanor Ventures, said: “Astanor’s core thesis, a healthy food system starts from the soil, is fully in line with the strategy of Aphea.Bio. Toxicity of chemical pesticides and the urgent need to restore the soil microbiome argue in favor of new innovative players such as Aphea.Bio. We are certain that with such an outstanding team and technology, Aphea.Bio will pave the way towards a more sustainable agrifood sector.”
Steven Vandenabeele, CSO at Aphea.Bio added: “We succeed in using microorganisms via seed treatment as a growth promoter in wheat, achieving significantly higher yields under reduced fertilizer regimes. Besides that, our field trial campaigns indicate that our sprayable applications to protect wheat against the economically most important fungal diseases offer a sustainable alternative to chemical pesticides.”
Johan De Saegher, chairman of the board, said: “Aphea.Bio’s products will provide disruptive full- fledged bio-based s0lutions to the farmers to control diseases and pests and to use more efficiently fertilizers in the main food crops. With its biostimulant and biopesticides product concepts, Aphea.Bio anticipates the vision of using at least 20% less fertilizers and halving the use of chemical pesticides by 2030, as outlined in the Farm-to-Fork strategy, a cornerstone of the European Green Deal.”
Encouraged by promising data, propelled by an outstanding team, motivated by the European Green Deal ambitions and backed by a solid consortium of investors, Aphea.Bio is now up for the further development and scale up of the most promising products.
Isabel Vercauteren concluded “We are thrilled to bring the company to this next important phase towards launching our products to the market.”
EuroChem Group AG, a leading global fertilizer producer, and Belgium-based biotechnology company Aphea.Bio announce the signing of a research and development agreement on the development of next-generation fertilizer technologies designed to significantly boost the take-up of key nutrients by plants.
Dr Thomas Mannheim (head of Global R&D for Premium Products EuroChem): “This agreement will further strengthen EuroChem’s commitment to investing in innovation. We are committed to helping farmers optimize resource use and enabling them to enhance their yields and economic benefit.”
Dr. Isabel Vercauteren (CEO Aphea.Bio): “We are delighted to have signed EuroChem as our first commercial partner. EuroChem has deep expertise in the mineral fertilizer sector and we look forward to a long and fruitful collaboration together.”
Aphea.Bio is a spin-off of a VIB, Ghent University and KU Leuven that develops sustainable agricultural products based on natural microorganisms to increase crop yields and to protect them against specific fungal diseases. Headquartered in Ghent, Belgium, Aphea.Bio is led by CEO Dr. Isabel Vercauteren and CSO Dr. Steven Vandenabeele.
For more information : https://aphea.bio/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.